Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer’s Disease with APP Osaka Mutation

We previously identified a novel mutation in amyloid precursor protein from a Japanese pedigree of familial Alzheimer’s disease, FAD (Osaka). Our previous positron emission tomography (PET) study revealed that amyloid β (Aβ) accumulation was negligible in two sister cases of this pedigree, indicating a possibility that this mutation induces dementia without forming senile plaques. To further explore the relationship between Aβ, tau and neurodegeneration, we performed tau and Aβ PET imaging in the proband of FAD (Osaka) and in patients with sporadic Alzheimer’s disease (SAD) and healthy controls (HCs). The FAD (Osaka) patient showed higher uptake of tau PET tracer in the frontal, lateral temporal, and parietal cortices, posterior cingulate gyrus and precuneus than the HCs (>2.5 SD) and in the lateral temporal and parietal cortices than the SAD patients (>2 SD). Most noticeably, heavy tau tracer accumulation in the cerebellum was found only in the FAD (Osaka) patient. Scatter plot analysis of the two tracers revealed that FAD (Osaka) exhibits a distinguishing pattern with a heavy tau burden and subtle Aβ accumulation in the cerebral cortex and cerebellum. These observations support our hypothesis that Aβ can induce tau accumulation and neuronal degeneration without forming senile plaques.

[1]  Yasuyoshi Watanabe,et al.  Staging of tau distribution by positron emission tomography may be useful in clinical staging of Alzheimer disease , 2020 .

[2]  T. Tomiyama,et al.  APP Osaka Mutation in Familial Alzheimer’s Disease—Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance , 2020, International journal of molecular sciences.

[3]  K. Servick Doubts persist for claimed Alzheimer's drug. , 2019, Science.

[4]  David T. Jones,et al.  The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.

[5]  J. Attems,et al.  Neuropathology and biochemistry of early onset familial Alzheimer’s disease caused by presenilin-1 missense mutation Thr116Asn , 2018, Journal of Neural Transmission.

[6]  M. Mintun,et al.  Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.

[7]  Takashi Kato,et al.  Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Virginia M. Y. Lee,et al.  Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies , 2017, Brain : a journal of neurology.

[9]  Ming-Rong Zhang,et al.  Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study , 2016, Alzheimer's & dementia.

[10]  Y. Um,et al.  Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro , 2016, Annals of Nuclear Medicine.

[11]  Ming-Rong Zhang,et al.  PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.

[12]  Lin Xie,et al.  Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.

[13]  Nick C Fox,et al.  Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.

[14]  A. Takashima,et al.  Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice , 2014, Acta Neuropathologica.

[15]  J. Trojanowski,et al.  Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.

[16]  H. Mori,et al.  Clinical Course of Patients with Familial Early-Onset Alzheimer’s Disease Potentially Lacking Senile Plaques Bearing the E693Δ Mutation in Amyloid Precursor Protein , 2011, Dementia and Geriatric Cognitive Disorders.

[17]  F. Lopera,et al.  Deposition of Hyperphosphorylated Tau in Cerebellum of PS1 E280A Alzheimer's Disease , 2011, Brain pathology.

[18]  W. Jagust,et al.  The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.

[19]  Rie Teraoka,et al.  A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.

[20]  Wei Zhu,et al.  Outcome over seven years of healthy adults with and without subjective cognitive impairment , 2010, Alzheimer's & Dementia.

[21]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[22]  Yasuyoshi Watanabe,et al.  A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.

[23]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[24]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[25]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[26]  Martin N Rossor,et al.  Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val→Ile) mutation cases: A morphometric investigation , 1996, Journal of the Neurological Sciences.

[27]  Kenneth S. Kosik,et al.  The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.

[28]  A. Alavi,et al.  MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.

[29]  Emiliano Bruner,et al.  The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline. , 2018, Brain : a journal of neurology.

[30]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.